CD38 antigen to target the CD38 gene is inactivated and manipulated, for immunotherapy of cells

文件类型：PDF文档
文件大小：2866K
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.